Source: www.news.sanofi.us
The U.S. Food and Drug Administrator (FDA) has given its approval for Sanofi and Merck’s drug VAXELIS. This drug can be used as a 3-dose series with children from 6 weeks through 4 years of age (prior to the 5th birthday) to protect against diphtheria, tetanus and pertussis (DTP) as well as polio, hepatitis B virus and invasive disease caused by Haemophilus influenzae type B (Hib). VAXELIS was jointly developed by Sanofi, and Merck & Co, and is expected to be available in the U.S. by 2020.
